1. Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models.
- Author
-
Porter, L. H., Zhu, J. J., Lister, N. L., Harrison, S. G., Keerthikumar, S., Goode, D. L., Urban, R. Quezada, Byrne, D. J., Azad, A., Vela, I., Hofman, M. S., Neeson, P. J., Darcy, P. K., Trapani, J. A., Taylor, R. A., and Risbridger, G. P.
- Subjects
T cells ,ANDROGEN receptors ,TUMOR microenvironment ,PROSTATE cancer ,T cell receptors ,CARBOPLATIN ,CHIMERIC antigen receptors ,EXTRACELLULAR matrix - Abstract
Chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for hematological malignancies. However, CAR T cells are less efficient against solid tumors, largely due to poor infiltration resulting from the immunosuppressive nature of the tumor microenvironment (TME). Here, we assessed the efficacy of Lewis Y antigen (Le
Y )-specific CAR T cells in patient-derived xenograft (PDX) models of prostate cancer. In vitro, LeY CAR T cells directly killed organoids derived from androgen receptor (AR)-positive or AR-null PDXs. In vivo, although LeY CAR T cells alone did not reduce tumor growth, a single prior dose of carboplatin reduced tumor burden. Carboplatin had a pro-inflammatory effect on the TME that facilitated early and durable CAR T cell infiltration, including an altered cancer-associated fibroblast phenotype, enhanced extracellular matrix degradation and re-oriented M1 macrophage differentiation. In a PDX less sensitive to carboplatin, CAR T cell infiltration was dampened; however, a reduction in tumor burden was still observed with increased T cell activation. These findings indicate that carboplatin improves the efficacy of CAR T cell treatment, with the extent of the response dependent on changes induced within the TME. Although CAR T therapy has greatly improved the therapeutic prospects for haematological malignancies, it is not yet widely used for solid tumors, such as prostate cancer. Here, using prostate cancer patient-derived xenografts, the authors demonstrate the efficacy of CAR T cells specific for Lewis Y antigen when combined with low-dose carboplatin. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF